AG
Antonio Gasbarrini
Elite in Lactose Intolerance

Antonio Gasbarrini

Policlinico Gemelli - Università Cattolica Del Sacro Cuore
Italy
Elite
 in Lactose Intolerance
Clinical Trials:Currently Recruiting for 3 Trials
About|Expertise|Location|Research
Areas of Expertise

Many experts have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a expert treats and their level of experience.

Check Antonio Gasbarrini's experience treating your condition:
About Antonio Gasbarrini

Antonio Gasbarrini practices in Roma, Italy. Gasbarrini is rated as an Elite expert by MediFind in the treatment of Lactose Intolerance. He is also highly rated in 62 other conditions, according to our data. His top areas of expertise are Small Bowel Bacterial Overgrowth, Lactose Intolerance, Liver Cancer, Liver Transplant, and Endoscopy.

His clinical research consists of co-authoring 976 peer reviewed articles and participating in 12 clinical trials in the past 15 years. In particular, he has co-authored 9 articles in the study of Lactose Intolerance.

Locations
Roma, Italy
Background & Education
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Recruiting
Publish Date: April 05, 2023
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
Enrollment Status: Recruiting
Publish Date: March 27, 2023
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Recruiting
Publish Date: October 27, 2022
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer
Enrollment Status: Active, not recruiting
Publish Date: March 24, 2023
Intervention Type: Drug
Study Drug: Panitumumab
Study Phase: Phase 2
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Active, not recruiting
Publish Date: November 25, 2022
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Active, not recruiting
Publish Date: August 31, 2022
Intervention Type: Drug
Study Drugs: MirikizumabUstekinumab
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 307)
Enrollment Status: Terminated
Publish Date: March 31, 2022
Intervention Type: Drug, Other
Study Drug: Ontamalimab
Study Phase: Phase 3
Fecal Microbiota Transplantation for the Treatment of Metabolic Syndrome
Enrollment Status: Withdrawn
Publish Date: July 15, 2020
Intervention Type: Other
Study Phase: Phase 2
Major Determinants of COVID-19 Associated Pneumonia
Enrollment Status: Completed
Publish Date: June 19, 2020
Intervention Type: Diagnostic Test
Time of Recovery and Prognostic Factors of COVID-19 Pneumonia
Enrollment Status: Completed
Publish Date: May 14, 2020
Sorafenib in the First Line Treatment of Advanced Hepatocellular Carcinoma With Child-Pugh Liver Function Class B: Multicentre Phase 3 Randomized Trial
Enrollment Status: Terminated
Publish Date: March 28, 2017
Intervention Type: Drug, Other
Study Phase: Phase 3
Efficacy and Tolerability of a New Oral Extended-Release Formulation Containing Parnaparin Sodium (CB-01-05-MMX™), Administered as Add-on Therapy to Oral Mesalazine or Other 5-ASA Derivatives, in Patients With Active, Left-Sided, Mild to Moderate Ulcerative Colitis. A Multicentre Randomized, Double-Blind, Comparative Study Versus Placebo.
Enrollment Status: Completed
Publish Date: March 25, 2009
Intervention Type: Procedure
Study Phase: Phase 2
View 9 Less Clinical Trials -
976 Total Publications
Assessment of small intestinal bacterial overgrowth and methane production in patients on chronic proton-pump inhibitor treatment: prevalence and role of rifaximin in its management in primary care.
Journal: Minerva gastroenterology
Published: March 21, 2023
Save this expert for later
Sign Up
Looking for the best expert for you?
Start Here
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more